LYON, France--(BUSINESS WIRE)--Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback